- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
Data from the DOH - Epidemiology Bureau shows that only 44o/o of allpeople diagnosed with HIV from 2010 to 2015 were started on Anti-Retroviral Therapy (ART). Based on the 2013 external evaluation of the health sector's response to HIV in the Philippines, long turn-around time of confirmatory HIV testing is one of the identified barriers for prompt referral and management. In the interim, this memorandum shall ensure linkage to care of clients with reactive HIV screening test to immediately be assessed by Treatment hubs, satellite treatment hubs and HIV primary care clinics in order to provide early treatment and management.
Within the continuum of reproductive health care, antenatal care (ANC) provides a platform for important healthcare functions, including health promotion, screening and diagnosis, and disease prevention. It has been established that, by implementing timely and appropriate evidence-based practices, ANC can save lives.
Endorsed, by the UN Secretary-General, this is a comprehensive WHO guideline on routine ANC for pregnant women and adolescent girls. It aims to complement existing WHO guidelines on the management of specific pregnancy-related complications. The guidance aims to capture the complex nature of the issues surrounding ANC health care practices and delivery, and to prioritize person-centred health and well-being, not only the prevention of death and morbidity, in accordance with a human rights-based approach.
Keywords: ANC, women, pregnancy, children, adolescent
Until recently, diagnosis and treatment of HCV was complex. Suitable tools for screening and diagnosis were lacking, and treatment was hampered by limited efficacy and severe side effects. New medicines for the treatment of HCV have revolutionized HCV treatment. Combinations of these new medicines, which are generally well-tolerated and effective, can cure HCV in 12 weeks. This offers a huge opportunity to address HCV, in particularly among HIV/HCV co-infected people, who are more vulnerable as they progress faster to serious disease than HCV mono-infected people.
Antimicrobial resistance (AMR) has become one of the biggest threats to global health and endangers other major priorities, such as human development. All around the world, many common infections are becoming resistant to the antimicrobial medicines used to treat them, resulting in longer illnesses and more deaths. At the same time, not enough new antimicrobial drugs, especially antibiotics, are being developed to replace older and increasingly ineffective ones.
Global leaders will meet at the United Nations General Assembly in New York in September 2016 to commit to fighting antimicrobial resistance together. This is only the fourth time in the history of the UN that a health topic is discussed at the General Assembly (HIV, noncommunicable diseases, and Ebola were the others). Heads of State and Heads of Delegations are expected to address the seriousness and scope of the situation and to agree on sustainable, multisectoral approaches to addressing antimicrobial resistance.
Keywords: WHO, AMR, Antimicrobial Resistance, High-level Meeting
The global HIV epidemic claimed fewer lives in 2015 than at any point in almost two decades, and fewer people became newly infected with HIV than in any year since 1991. The list of countries on the brink of eliminating new HIV infections among children keeps growing. A massive expansion of antiretroviral therapy (ART) has reduced the global number of people dying from HIV-related causes to about 1.1 million in 2015 – 45% fewer than in 2005. UNAIDS/WHO estimates show that more than 18 million people were receiving ART in mid-2016.
Whether it’s the rising price of the EpiPen, or new outbreaks of diseases, like Ebola, Zika and yellow fever, the rising costs of health technologies and the lack of new tools to tackle health problems, like antimicrobial resistance, is a problem in rich and poor countries alike.
Keywords: TRIPS, Antimicrobial resistance (AMR), health technology, access
In 2000, when the International AIDS Conference was last held in Durban, South Africa, a basic antiretroviral (ARV) regimen cost over US$10,000 per person per year (PPPY), multilateral programmes funding the fight against HIV, TB, and malaria did not exist, and many donors – such as the US government – had yet to provide a single dollar for antiretroviral treatment in resource-limited countries.
The sexual partners and drug injecting partners of people diagnosed with HIV infection have an increased probability of also being HIV-positive.
This infographic details the process for developing long-acting injectables for PrEP and treatment.
Keywords: HIV, ARV, PrEP, treatment, prevention, testing
This manual for developing national action plans to address antimicrobial resistance has been developed at the request of the World Health Assembly to assist countries in the initial phase of developing new, or refining existing national action plans in line with the strategic objectives of the Global Action Plan. It proposes an incremental approach that countries can adapt to the specific needs, circumstances and available resources of each individual country. Details of actions to be taken will vary according to national contexts.